Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $5.7 million.

  • Arcturus Therapeutics Holdings' Share-based Compensation fell 39.65% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 27.09%. This contributed to the annual value of $38.0 million for FY2024, which is 9.64% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Share-based Compensation stood at $5.7 million, which was down 7.60% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Share-based Compensation registered a high of $10.1 million during Q1 2024, and its lowest value of $5.7 million during Q3 2025.
  • For the 3-year period, Arcturus Therapeutics Holdings' Share-based Compensation averaged around $8.3 million, with its median value being $8.8 million (2023).
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Share-based Compensation skyrocketed by 722.97% in 2021, and later crashed by 39.65% in 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Share-based Compensation (Quarterly) stood at $7.5 million in 2021, then dropped by 13.14% to $6.5 million in 2022, then soared by 34.99% to $8.8 million in 2023, then increased by 1.91% to $9.0 million in 2024, then slumped by 39.65% to $5.7 million in 2025.
  • Its Share-based Compensation was $5.7 million in Q3 2025, compared to $6.2 million in Q2 2025 and $6.7 million in Q1 2025.